Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Executives On The Move: New CEOs Appointed At Arcellx, KSQ Therapeutics

Executive Summary

New board directors named at Eli Lilly, Immunicum, and Talaris Therapeutics.

You may also be interested in...



Arcellx Raises $115m To Advance Novel T-Cell Therapies

The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.

Coronavirus Update: Pfizer/BioNTech Vaccine Shows Antibody Response In Young Kids

The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light, and vaccines from other Indian firms progress.

Pipeline Watch: Phase III Readouts In NSCLC, Ovarian Cancer And More

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

UsernamePublicRestriction

Register

SC143712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel